Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Prof Kathleen Moore, MD
University of Oklahoma Health Sciences Center, Oklahoma City, USA
Principal InvestigatorKOL profile → - Prof Paul DiSilvestro, MD
Women & Infants Hospital, Providence, Rhode Island, USA
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
177 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mercy Hospital for Women
Heidelberg, Australia
- the Royal Womens Hospital
Parkville, Australia
- Prince of Wales Hospital
Randwick, Australia
- Centro Diagnóstico Barretos
Barretos, Brazil
- Hospital Araujo Jorge
Goiânia, Brazil
- Centro de Novos Tratamentos Itajai
Itajaí, Brazil
- Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil
- Irmandade Da Santa Casa de Misericordia de Porto Alagre
Porto Alegre, Brazil
- Hospital de Base São José Do Rio Preto
São José do Rio Preto, Brazil
- Centro de Referencia Da Saude Da Mulher
São Paulo, Brazil
- Instituto Do Câncer de São Paulo
São Paulo, Brazil
- Juravinski Cancer Centre
Hamilton, Ontario, Canada
- London Health Sciences Centre
London, Ontario, Canada
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Sunnybrook Health Sciences Center
Toronto, Ontario, Canada
- Chum - Hopital Norte-Dame
Montreal, Quebec, Canada
- Royal Victoria Hospital
Montreal, Quebec, Canada
- Hotel-Dieu de Quebec
Québec, Quebec, Canada
- Beijing Cancer Hospital
Beijing, China
- the Tumor Hospital Affiliated To China Medical Science Insti
Beijing, China
- 1st Hospital of Jilin University
Changchun, China
- Jilin Provincial Cancer Hospital
Changchun, China
- Hunan Cancer Hospital
Changsha, China
- West China Hospital Affiliated To Sichuan University
Chengdu, China
- Chongqing Cancer Hospital
Chongqing, China
- Research Site
Guangzhou, China
- Women'S Hospital, Zhejaing University School of Medicine
Hangzhou, China
- the Tumour Hospital of Harbin Medical University
Harbin, China
- Zhejiang Cancer Hospital, Huangzhou
Huangzhou, China
- Jinan, Qi Lu Hosp. of Sd Univ.
Jinan, China
- Obstetris and Gynecology Hospital of Fudan University
Shanghai, China
- Shanghai Cancer Hospital of Fudan University
Shanghai, China
- the First Affiliated Hospital of Soochow Universit
Suzhou, China
- First Affiliated Hospital College of Xianjiaotong University
Xi'an, China
- Institut Bergonie
Bordeaux, France
- Cac François Baclesse
Caen, France
- 69lyon, C Bérard, Onco
Lyon, France
- Centre Catherine de Sienne
Nantes, France
- 75paris, H Tenon, Onco
Paris, France
- Centre Alexis Vautrin
Vandœuvre-lès-Nancy, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Aug 2013
- Primary completion
- 17 May 2018
- Completion
- 29 Aug 2028
- Last update posted
- 10 Dec 2025
- Registered enrollment
- 450
- Registry id
- NCT01844986
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.